Meridian is seeking participants for a clinical trial of an oral contraceptive (birth control) medication. The goal of this study is to assess the investigational medication’s safety, tolerability, and its effect on pregnancy rates and bleeding/spotting.
- Must be premenopausal and age 14 to 35
- Must be sexually active, must engage in vaginal intercourse at least once per month, and should not routinely use any other form of contraception
- Must not desire a pregnancy within 1 year following screening
- Must provide blood and urine samples throughout the study
- Must have a history of regular menstrual cycles of 21 to 35 days prior to the use of any hormonal contraceptive
- Will receive compensation for study-related time
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can talk to a Meridian enrollment specialist about this study by calling (402) 934-7563 (Omaha), (712) 639-6200 (Hastings and Grand Island), or (912) 623-2240 (New York).
Submit your information
- Grand Island: Meridian Clinical Research, 3537 West 13th St., Ste. 100, Grand Island, NE 68803
- Hastings: Meridian Clinical Research, 2115 N. Kansas Ave., Suite 104, Hastings, NE 68901
- Omaha: Meridian Clinical Research, 3319 N 107th St, Omaha, NE 68134
- Endwell: Meridian Clinical Research, 415 Hooper Road, Endwell, NY 13760
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.